The EMBARK Study is evaluating whether an investigational drug (a drug not approved for clinical use) works as a treatment for moderate to severe atopic dermatitis.
In the first phase, participants are randomly assigned to 1 of 2 groups and receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active medicine), both administered as a subcutaneous injection (under the skin).
In the second phase, all participants receive the investigational drug.
The EMBARK Studyinvolves 20 study visits over the course of up to 1 year and 3 months (66 weeks).
Approximately 80 participants will be enrolled globally, and they may be reimbursed for travel and expenses.
The investigational drug being studied in patients with atopic dermatitis is under clinical development and is not approved for use by regulatory health authorities. Safety and effectiveness are under evaluation.
